MDCX
Medicus Pharma Ltd. Common StockMDCX
MDCX
About: Medicus Pharma Ltd is a clinical-stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.
–
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
288%
upside
Avg. target
$10
288%
upside
High target
$10
288%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Maxim Group Jason McCarthy 26% 1-year accuracy 7 / 27 met price target | 288%upside $10 | Buy Initiated | 17 Dec 2024 |
Financial journalist opinion
Based on 8 articles about MDCX published over the past 30 days
Positive
Proactive Investors
2 days ago
Medicus Pharma achieves FDA MUMS approval for equine squamous cell carcinoma patch - ICYMI
Earlier this week Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) announced that its innovative skin patch treatment has received Minor Use and Minor Species (MUMS) designation from the FDA. The patch, which uses a cellulose-based, doxorubicin-loaded design, is aimed at treating squamous cell carcinoma in horses.
Positive
Proactive Investors
1 week ago
Medicus Pharma's horse skin cancer treatment wins MUMS designation from FDA
Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) announced that the Food and Drug Administration has granted Minor Use in Major Species (MUMS) designation for its Investigational New Animal Drug, a dissolvable Doxorubicin-containing microneedle array (D-MNA) patch targeting external squamous cell carcinoma in horses. The MUMS designation, akin to the Orphan Drug status for human medicine, provides Medicus with a seven-year exclusive marketing period following product approval or conditional approval, contingent on meeting the program's requirements.
Neutral
Newsfile Corp
1 week ago
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
Company to Submit Product Development Plan to Treat External Squamous Cell Carcinoma (SCC) in Horses Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - December 12, 2024) - Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce that its Investigational New Animal Drug (INAD File No.013880) has received Minor Use in Major Species Designation ("MUMS") from the U.S. Food and Drug Administration ("FDA") for its dissolvable Doxorubin-containing microneedle array (D-MNA) to treat external squamous cell carcinoma (SCC) in horses.
Neutral
GlobeNewsWire
1 week ago
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
Company to Submit Product Development Plan to Treat External Squamous Cell Carcinoma (SCC) in Horses Company to Submit Product Development Plan to Treat External Squamous Cell Carcinoma (SCC) in Horses
Neutral
Proactive Investors
2 weeks ago
Medicus Pharma CEO on basal-cell carcinoma trial progress – ICYMI
Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) provided an update on its phase two clinical trial for a novel non-invasive treatment targeting basal-cell carcinoma. CEO Raza Bokhari told Proactive that 25% of patient recruitment for the U.S.-based trial has been completed.
Positive
Proactive Investors
2 weeks ago
Medicus Pharma eyes pivotal trial for novel skin cancer therapy as Phase 2 enrollment progresses
Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) announced that its Phase 2 clinical study targeting basal cell carcinoma (BCC) is now being conducted at nine clinical sites across the United States, with more than 25% of the 60 patients expected to be enrolled in the study already randomized. An interim data analysis is planned for Q1 2025, and Medicus intends to submit these findings to the US Food and Drug Administration (FDA) to request a Type C meeting in Q2 2025, the company said on Monday.
Positive
Proactive Investors
3 weeks ago
Medicus Pharma partners with Swanielle to expand basal cell carcinoma study into Asia-Pacific
Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) announced it has entered into an agreement with healthcare consulting firm Swanielle to explore expanding its Phase 2 clinical study for treating Basal Cell Carcinoma (BCC) into the Asia-Pacific region. The collaboration aims to identify potential pharmaceutical or biotech partners in Southeast Asia to facilitate this expansion.
Neutral
Newsfile Corp
3 weeks ago
Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region
Provides Update on SKNJCT-003 Phase 2 Clinical Study for Treatment of Nodular Basal Cell Carcinoma (BCC) Currently Underway in United States Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - December 2, 2024) - Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce an agreement with Swanielle Inc. ("Swanielle") to explore expansion of Phase 2 clinical study for treatment of Basal Cell Carcinoma (BCC) in the Asia-pacific region.
Positive
Proactive Investors
1 month ago
Medicus Pharma unveils ex-GSK and Pfizer senior as chief medical officer
Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) Ltd has announced the appointment of Faisal Mehmud, formerly of GSK PLC (LSE:GSK, NYSE:GSK) and Pfizer Inc (NYSE:PFE, ETR:PFE), as chief medical officer. Mehmud has over 20 years of experience as a senior medical executive in clinical development, medical affairs and drug safety, Medicus said on Monday.
Neutral
GlobeNewsWire
1 month ago
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer
Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D Program Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D Program
Charts implemented using Lightweight Charts™